» Articles » PMID: 37762689

Endothelial Dysfunction in Systemic Sclerosis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Sep 28
PMID 37762689
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic sclerosis, commonly known as scleroderma, is an autoimmune disorder characterized by vascular abnormalities, autoimmunity, and multiorgan fibrosis. The exact etiology is not known but believed to be triggered by environmental agents in a genetically susceptible host. Vascular symptoms such as the Raynaud phenomenon often precede other fibrotic manifestations such as skin thickening indicating that vascular dysfunction is the primary event. Endothelial damage and activation occur early, possibly triggered by various infectious agents and autoantibodies. Endothelial dysfunction, along with defects in endothelial progenitor cells, leads to defective angiogenesis and vasculogenesis. Endothelial to mesenchymal cell transformation is another seminal event during pathogenesis that progresses to tissue fibrosis. The goal of the review is to discuss the molecular aspect of the endothelial dysfunction that leads to the development of systemic sclerosis.

Citing Articles

Endothelin-1 as a Candidate Biomarker of Systemic Sclerosis: A GRADE-Assessed Systematic Review and Meta-Analysis With Meta-Regression.

Mangoni A, Zinellu A Biomark Insights. 2025; 20:11772719251318555.

PMID: 39990053 PMC: 11846126. DOI: 10.1177/11772719251318555.


Vascular endothelial growth factor as a potential biomarker in systemic sclerosis: a systematic review and meta-analysis.

Zinellu A, Mangoni A Front Immunol. 2024; 15:1442913.

PMID: 39669565 PMC: 11634811. DOI: 10.3389/fimmu.2024.1442913.


Progression, Management, and Outcome of Aortic Valve Stenosis in Systemic Sclerosis: A Case Series.

Vergara A, Orlando A, Caiazza E, Vettori S, Cuomo G, Argiento P J Cardiovasc Dev Dis. 2024; 11(9).

PMID: 39330332 PMC: 11432032. DOI: 10.3390/jcdd11090274.


Circulating cell adhesion molecules in systemic sclerosis: a systematic review and meta-analysis.

Mangoni A, Zinellu A Front Immunol. 2024; 15:1438302.

PMID: 39234240 PMC: 11371573. DOI: 10.3389/fimmu.2024.1438302.


Biomarkers reflecting the pathogenesis, clinical manifestations, and guide therapeutic approach in systemic sclerosis: a narrative review.

Bazso A, Szodoray P, Shoenfeld Y, Kiss E Clin Rheumatol. 2024; 43(10):3055-3072.

PMID: 39210206 PMC: 11442557. DOI: 10.1007/s10067-024-07123-y.


References
1.
Prescott R, Freemont A, Jones C, Hoyland J, Fielding P . Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol. 1992; 166(3):255-63. DOI: 10.1002/path.1711660307. View

2.
Giordano N, Papakostas P, Pecetti G, Nuti R . Cytokine modulation by endothelin-1 and possible therapeutic implications in systemic sclerosis. J Biol Regul Homeost Agents. 2012; 25(4):487-92. View

3.
Avouac J, Juin F, Wipff J, Couraud P, Chiocchia G, Kahan A . Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis. 2008; 67(10):1455-60. DOI: 10.1136/ard.2007.082131. View

4.
Kuwana M, Okazaki Y . Brief report: impaired in vivo neovascularization capacity of endothelial progenitor cells in patients with systemic sclerosis. Arthritis Rheumatol. 2014; 66(5):1300-5. DOI: 10.1002/art.38326. View

5.
Ennis H, Hughes M, Anderson M, Wilkinson J, Herrick A . Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2016; 2:CD002069. PMC: 7065590. DOI: 10.1002/14651858.CD002069.pub5. View